Amgen, MariTide and weight loss
That's a potential steal. The average stock in the Health Care Select Sector SPDR Fund trades at a multiple of just under 18 ...
(Reuters) - Amgen posted a higher quarterly profit on Tuesday as product sales rose 11% and said late-stage studies of key obesity drug candidate MariTide will start before mid-year but regulators ...
MariTide's development in obesity treatment is crucial, but concerns about its progress and competition from Novo and Lilly remain. Despite strong performance, Amgen's high debt levels and ...
Eli Lilly Chief Scientific Officer Dan Skovronsky spoke to CNBC about obesity pills and more on the future of weight loss.
Amgen (AMGN) is getting closer to challenging the weight-loss drug duopoly of Novo Nordisk (NVO), the maker of Ozempic and Wegovy, and Eli Lilly (LLY), which produces Zepbound.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback